 Hypolipidemic Agents
"Hypolipidemic Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Substances that lower the levels of certain LIPIDS in the BLOOD. They are used to treat HYPERLIPIDEMIAS.
| Descriptor ID |
D000960
|
| MeSH Number(s) |
D27.505.519.186.071 D27.505.954.557.500
|
| Concept/Terms |
Hypolipidemic Agents- Hypolipidemic Agents
- Agents, Hypolipidemic
- Antihyperlipidemics
- Hypolipidemic Drugs
- Drugs, Hypolipidemic
- Antilipemic Drugs
- Drugs, Antilipemic
- Antilipemics
- Antihyperlipemics
- Antilipemic Agents
- Agents, Antilipemic
|
Below are MeSH descriptors whose meaning is more general than "Hypolipidemic Agents".
Below are MeSH descriptors whose meaning is more specific than "Hypolipidemic Agents".
This graph shows the total number of publications written about "Hypolipidemic Agents" by people in this website by year, and whether "Hypolipidemic Agents" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2000 | 2 | 1 | 3 | | 2003 | 0 | 2 | 2 | | 2004 | 2 | 0 | 2 | | 2005 | 1 | 4 | 5 | | 2006 | 3 | 0 | 3 | | 2007 | 6 | 1 | 7 | | 2008 | 3 | 3 | 6 | | 2009 | 1 | 2 | 3 | | 2010 | 4 | 0 | 4 | | 2011 | 3 | 3 | 6 | | 2012 | 2 | 1 | 3 | | 2013 | 2 | 0 | 2 | | 2015 | 0 | 1 | 1 | | 2016 | 1 | 0 | 1 | | 2017 | 3 | 2 | 5 | | 2018 | 1 | 2 | 3 | | 2020 | 1 | 1 | 2 | | 2021 | 1 | 2 | 3 | | 2022 | 0 | 2 | 2 | | 2025 | 2 | 2 | 4 |
To return to the timeline, click here.
Below are the most recent publications written about "Hypolipidemic Agents" by people in Profiles.
-
Walker M, Riggs KA, Rohatgi A, Beckman J, Addo T, Girotra S, Bonaca MP, Armstrong E, Kumbhani DJ. Role of Lipids and Lipid Management Therapy Among Patients With Peripheral Artery Disease: A Reappraisal of the Current Evidence and Future Directions. J Am Heart Assoc. 2025 Oct 07; 14(19):e039734.
-
Kapoor E, Sheehan KA, Yu AYX, Kurdyak P, Casaubon LK, Porter J, Fang J, Kapral MK. Association Between Schizophrenia and Adherence to Medications for Secondary Stroke Prevention. Stroke. 2025 Oct; 56(10):3090-3094.
-
Muscoli S, Cimmino G, Canonico ME, Cesaro A, De Rosa G, De Rosa S, Coronelli MM, Natale F, Perrone MA, Sticchi A, Sorrentino S, Sucato V, Renda G, Paolillo S, Indolfi C, Calabrò P, Perrone Filardi P, Cirillo P. Comprehensive insights into peripheral artery disease: an overview from the working groups of pathogenesis of atherosclerosis and thrombosis of the Italian Society of Cardiology. J Cardiovasc Med (Hagerstown). 2025 Jul 01; 26(7):325-338.
-
Patel SB, Wyne KL, Afreen S, Belalcazar LM, Bird MD, Coles S, Marrs JC, Peng CC, Pulipati VP, Sultan S, Zilbermint M. American Association of Clinical Endocrinology Clinical Practice Guideline on Pharmacologic Management of Adults With Dyslipidemia. Endocr Pract. 2025 Feb; 31(2):236-262.
-
Ballantyne CM, Varughese MG, Abushamat LA. Lipid-Lowering Therapy in the Elderly: Are Current Guidelines a Sign of Ageism in Medical Care? J Am Coll Cardiol. 2023 04 11; 81(14):1350-1352.
-
Koenig W, Conde LG, Landmesser U, Leiter LA, Ray KK, Schwartz GG, Wright RS, Han J, Raal FJ. Efficacy and Safety of Inclisiran in Patients with Polyvascular Disease: Pooled, Post Hoc Analysis of the ORION-9, ORION-10, and ORION-11 Phase 3 Randomized Controlled Trials. Cardiovasc Drugs Ther. 2024 Jun; 38(3):493-503.
-
Machida T, Obara T, Miyazaki M, Inoue J, Mano N. Trends in drug prescriptions for type 2 diabetes, hypertension, and dyslipidemia among adults with non-alcoholic fatty liver disease. Ann Hepatol. 2022 Jul-Aug; 27(4):100699.
-
Hess CN, Cannon CP, Beckman JA, Goodney PP, Patel MR, Hiatt WR, Mues KE, Orroth KK, Shannon E, Bonaca MP. Effectiveness of Blood Lipid Management in Patients With Peripheral Artery Disease. J Am Coll Cardiol. 2021 06 22; 77(24):3016-3027.
-
Ballantyne CM, Bays H, Catapano AL, Goldberg A, Ray KK, Saseen JJ. Role of Bempedoic Acid in Clinical Practice. Cardiovasc Drugs Ther. 2021 08; 35(4):853-864.
-
Sabatine MS, Giugliano RP, Schwartz GG. Letter to the editor re: 'serious adverse events and deaths in PCSK9 inhibitor trials reported on ClinicalTrials.gov: a systematic review'. Expert Rev Clin Pharmacol. 2021 02; 14(2):281-282.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|